Remtolumab
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research[1][2].
Product Specifications
CAS Number
1791410-27-9
Product Name Alternative
ABT-122
UNSPSC
12352203
Target
Interleukin Related; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/remtolumab.html
Purity
99.24
Solubility
H2O
Smiles
[Remtolumab]
Molecular Weight
(198.31 kDa)
References & Citations
[1]Havnaer A, et al. Systemic therapies in psoriasis: an update on newly approved and pipeline biologics and oral treatments. Cutis. 2019 Aug;104 (2S) :17-20.|[2]Khatri A, et al. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. Clin Pharmacokinet. 2018 May;57 (5) :613-623.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
IL-17
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
